New combo aims to boost existing cancer Drug's power

NCT ID NCT06659341

Recruiting now Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-phase study tests a new experimental drug, BAY 3498264, combined with the approved cancer drug sotorasib in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see if the combination can make sotorasib work longer or better. About 104 participants will receive the drugs in cycles, and researchers will monitor side effects, drug levels, and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAY 3498264 (a SOS1 inhibitor) combined with sotorasib
What this could lead to: If successful, this combination could extend the time that sotorasib works in people with KRAS G12C cancers, potentially leading to longer disease control.
What could go wrong: This is a very early Phase 1 trial with only 104 participants. The main goal is safety and dosing, not proof of effectiveness. The combination may cause unexpected side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION

Contacts and locations

Locations

Border Medical oncology - Albury Wodonga Regional Cancer Centre
RECRUITING

Albury, New South Wales, 2640, Australia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
RECRUITING

Roma, 00168, Italy
Hospital Universitari Vall D Hebron | Oncologia
RECRUITING

Barcelona, 08035, Spain
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
RECRUITING

Rozzano, 20089, Italy
Institut Catala D'oncologia | Hospitalet | Oncologia
RECRUITING

Barcelona, 8907, Spain
Macquarie University Hospital - Oncology Department
RECRUITING

Macquarie Park, New South Wales, 2109, Australia
Peninsula and Southeast Oncology
RECRUITING

Frankston, Victoria, 3199, Australia
Rigshospitalet Copenhagen University Hospital | Oncology Department
RECRUITING

Copenhagen, Capital Region / Region Hovedstaden, 2100, Denmark
The Christie NHS Foundation Trust - Christie Hospital
RECRUITING

Manchester, Greater Manchester, M20 4BX, United Kingdom
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom